Who makes hyperbaric bupvacaine in Peribulbar block?

hyperbaric bupvacaine in Peribulbar block is developed by Cairo University.

What development phase is hyperbaric bupvacaine in Peribulbar block in?

hyperbaric bupvacaine in Peribulbar block is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

hyperbaric bupvacaine in Peribulbar block

Cairo University · FDA-approved active Small molecule Quality 0/100

Hyperbaric bupvacaine for peribulbar block is a marketed product developed by Cairo University, with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and the extended patent protection, which helps maintain a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	hyperbaric bupvacaine in Peribulbar block
Also known as	trial group
Sponsor	Cairo University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Heavy Bupivacaine in Peribulbar Block (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

hyperbaric bupvacaine in Peribulbar block CI brief — competitive landscape report
hyperbaric bupvacaine in Peribulbar block updates RSS · CI watch RSS
Cairo University portfolio CI